Prof Paolo Ghia speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He describes the background, design and latest results of the ASCEND trial, which examined the use of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukaemia (CLL).
Prof Ghia states that these results confirm the favourable efficacy and safety of acalabrutinib as seen in earlier analysis.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.